Larry Samuels from Pfizer: Study Looks at Connection Between Smoking Cessation Aids and Psychiatric Issues

As the effort continues to help people quit smoking research is being done to find the best treatment options available and any potential issues they may present in the process.

Larry Samuels, PhD, Senior Medical Director of Pfizer, discussed the results of the EAGLES study which looked at whether Chantix and other cessation options resulted in an increase in serious neuropsychiatric adverse events. Samuels said the data did not show any significant increase in the events and also showed its benefits in helping patients to quit smoking overall.